Actively Recruiting
Risk of Metachronous Findings After Detection of Serrated Lesions and High-grade Dysplasia With Surveillance Delay
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2025-02-11
730
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the risk of developing new advanced colorectal lesions after detecting serrated lesions (SLs) such as sessile serrated polyps and traditional serrated adenomas, as well as high-risk adenomas following high-grade dysplasia (HGD) found during initial colonoscopy. The study focuses on patients who experienced delays in follow-up colonoscopies to understand how interruptions in care may affect the detection of advanced lesions and colorectal cancer. This research addresses differing guidelines on surveillance timing and aims to clarify optimal intervals for repeat colonoscopies in these patients. Participants will undergo a standard colonoscopy, during which all visually identified polyps will be removed and analyzed by pathology according to institutional procedures. The study includes patients diagnosed with SL or HGD from 2010 to 2022 who lacked timely follow-up. These patients will be contacted and invited for follow-up colonoscopy as part of routine clinical care to assess the occurrence of new lesions after delayed surveillance. Throughout the study, data collected will include patient demographics, medical and family history, colonoscopy details such as indication, bowel preparation quality, withdrawal time, polyp characteristics, and any complications. Researchers will measure rates of new advanced neoplasia and high-risk adenomas detected within one year after the initial diagnosis. This detailed evaluation aims to understand risks associated with surveillance delays and improve continuity of care for affected patients.
CONDITIONS
Brief Title
Risk of Metachronous Findings After Detection of Serrated Lesions and High-grade Dysplasia With Surveillance Delay
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 45 to 80 years
- Underwent colonoscopy between 2009 and 2022 at Montreal University Hospital Center (CHUM)
- Had one or more serrated lesions or high-grade dysplasia detected at initial colonoscopy
- Lacked follow-up colonoscopy within or beyond recommended surveillance intervals per 2020 USMSTF guidelines
You will not qualify if you...
- Diagnosis of inflammatory bowel disease
- Presence of hereditary colorectal cancer syndromes
- Diagnosis of colorectal cancer at initial colonoscopy
- Diagnosis of serrated polyposis syndrome
- Life expectancy too short to benefit from colonoscopy
- Follow-up colonoscopy not yet due according to USMSTF guidelines (except for certain high-risk cases)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (phone contact)
Duration - Up to 1 year
Participants who lack follow-up after initial detection of serrated lesions or high-grade dysplasia are observed through routine clinical follow-up including a follow-up colonoscopy.
1 follow-up colonoscopy visit
Trial Site Locations
Total: 1 location
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Actively Recruiting
Research Team
D
Daniel von Renteln, MD, PhD
J
Julie Fleury
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here